TY - JOUR T1 - Substrate Inhibition Kinetics for Cytochrome P450-Catalyzed Reactions JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 368 LP - 374 VL - 29 IS - 4 AU - Yuh Lin AU - Ping Lu AU - Cuyue Tang AU - Qin Mei AU - Grit Sandig AU - A. David Rodrigues AU - Thomas H. Rushmore AU - Magang Shou Y1 - 2001/04/01 UR - http://dmd.aspetjournals.org/content/29/4/368.abstract N2 - Most cytochrome P450 (P450 or CYP)-catalyzed reactions are adequately described by classical Michaelis-Menten kinetic parameters (e.g., Km andVmax), which are usually determined by a saturation profile of velocity of product formation versus substrate concentration. In turn, these parameters may be used to predict pharmacokinetics. However, some P450 enzymes exhibit atypical or non-Michaelis-Menten kinetics, due largely to substrate inhibition at higher concentrations of substrate. Although the mechanism of substrate inhibition is unknown, ignoring it and truncating the data can lead to erroneous estimates of kinetic parameters. In the present study, 13 P450 marker substrates were examined with 10 recombinant P450 proteins, and 6 were found, to varying degrees, to exhibit substrate inhibition. To understand the nature of the inhibition, a kinetic model was proposed (assuming that two binding sites exist on the enzyme) and used to fit the experimental data. The derived data indicated that 1) theKI values (substrate inhibition) were approximately 1.2- to 10-fold greater than the respectiveKS values; 2) bothKS and KI values may be affected by the interaction of the two bound substrates within the enzyme, exhibited by a factor α(α = 5.1–23.3); and 3) enzyme activity was inhibited markedly (39–97%) at excess concentrations of the substrates (β = 0.03–0.61). These findings suggest that substrates have access to both the inhibitory site and catalytic site simultaneously (KI >KS). Furthermore, the two sites, in the presence of substrate, can interact with each other. Therefore, the degree of inhibition of the enzyme is dependent on the concentration of the substrate (usually >KI) that sufficiently occupies the inhibitory site. The American Society for Pharmacology and Experimental Therapeutics ER -